A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer (Q44442164)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 March 2012

Language	Label	Description	Also known as
English	A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer	scientific article published on 14 March 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

A Dasari

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

L Gore

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

W A Messersmith

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

S Diab

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A Jimeno

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C D Weekes

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

K D Lewis

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

H A Drabkin

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

T W Flaig

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

D R Camidge

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

14 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

115-125

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

BAY 43-9006: early clinical data in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Vorinostat in solid and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Novel ubiquitin-dependent quality control in the endoplasmic reticulum.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

The BATTLE trial: personalizing therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9812-Z

21 January 2018

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/22415798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/22415798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAY-43-9006 Bayer/Onyx.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22415798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22415798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9812-Z

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44442164&oldid=2206650684"